- Details
- Zachary Klaassen speaks with Lisa Lowenstein about transitioning men from active surveillance to watchful waiting in prostate cancer management. Dr. Lowenstein shares insights from her research on patient and clinician perspectives, highlighting the challenges of convincing men to reduce their monitoring intensity. She describes developing a shared decision-making intervention to help guide these...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Daniel Lin discusses the implications of potentially reclassifying Grade Group 1 prostate cancer as non-cancer in the context of active surveillance. Dr. Lin highlights the current understanding of grade reclassification as a primary driver in active surveillance decisions, noting that upgrading...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Laurence Klotz discusses the challenges and pitfalls in active surveillance for prostate cancer. He highlights the dual goals of avoiding unnecessary treatment while identifying patients who would benefit from intervention. Dr. Klotz addresses issues leading to overtreatment, such as overgrading,...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Derya Tilki challenges the notion that Europe doesn't have issues with active surveillance uptake for prostate cancer, highlighting the heterogeneity across European countries. Dr. Tilki specifically mentions Germany, where only about 30% of eligible patients opt for active surveillance, partly d...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Quoc-Dien Trinh discusses the complexities surrounding active surveillance for prostate cancer in racial and ethnic minorities, particularly Black men. He reviews several studies highlighting disparities in outcomes, including higher rates of disease reclassification and adverse pathology in Blac...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Howard Wolinsky, a medical journalist and prostate cancer patient, shares his experience with active surveillance (AS) and presents findings from a survey of over 450 AS patients. He discusses the financial and emotional challenges faced by low-risk patients, including difficulties obtaining life...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Leszek Izdebski discusses the complex decision-making process for prostate cancer patients considering active surveillance (AS). He emphasizes the importance of quality of life considerations, noting that different patients have varying priorities, such as maintaining the ability to participate i...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Ingrid Hall discusses the CDC's involvement in active surveillance for localized prostate cancer. She highlights the 2011 State-of-the-Science Conference and subsequent research initiatives aimed at addressing gaps identified by the consensus panel, and emphasizes the CDC's commitment to supporti...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Felix Feng discusses the limitations of genomics and AI in resolving the prostate cancer nomenclature question. He emphasizes that current genomic tools have not proven effective in active surveillance contexts, citing studies showing limited prognostic value beyond clinical variables. Dr. Feng e...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts explore several aspects of prostate cancer diagnosis and active surveillance. The group raises questions about the financial toxicity of active surveillance, particularly for underserved populations. They also consider whether high-quality access to care could improve surveillance outcome...
|